
Charlotte E Teunissen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4340247/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alzheimer's disease. Lancet, The, 2021, 397, 1577-1590.	6.3	1,530
2	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177
3	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
4	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology, 2009, 73, 1914-1922.	1.5	653
5	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
6	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
7	Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. Journal of Neuroinflammation, 2013, 10, 35.	3.1	409
8	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	4.9	360
9	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
10	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348
11	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
12	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.4	310
13	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	1.2	307
14	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	0.6	280
15	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2012, 8, 65-73.	0.4	271
16	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology, 2012, 78, 47-54.	1.5	255
17	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254
18	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation ofÂβâ€ a myloid (1–42) in human cerebrospinal fluid. Alzheimer's and Dementia, 2016, 12, 517-52	26. ^{0.4}	254

#	Article	IF	CITATIONS
19	Inflammation markers in relation to cognition in a healthy aging population. Journal of Neuroimmunology, 2003, 134, 142-150.	1.1	250
20	The cerebrospinal fluid "Alzheimer profile― Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
21	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
22	Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurology, The, 2005, 4, 32-41.	4.9	230
23	Plasma Amyloid as Prescreener for the Earliest <scp>A</scp> lzheimer Pathological Changes. Annals of Neurology, 2018, 84, 648-658.	2.8	230
24	Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. Journal of Proteomics, 2014, 106, 191-204.	1.2	222
25	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
26	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
27	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	1.7	207
28	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Translational Psychiatry, 2021, 11, 27.	2.4	207
29	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Molecular Neurodegeneration, 2016, 11, 7.	4.4	198
30	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain, 2021, 144, 3505-3516.	3.7	198
31	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
32	Neurofilaments as biomarkers in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 552-556.	1.4	195
33	Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurology, 2021, 78, 1375.	4.5	195
34	Combination of CSF <i>N</i> -acetylaspartate and neurofilaments in multiple sclerosis. Neurology, 2009, 72, 1322-1329.	1.5	189
35	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurology, 2015, 72, 1275.	4.5	183
36	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179

#	Article	IF	CITATIONS
37	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiology of Aging, 2002, 23, 485-508.	1.5	173
38	Cerebrospinal fluid Aî²42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's and Dementia, 2013, 9, 481-487.	0.4	164
39	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
40	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161
41	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
42	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimer's and Dementia, 2018, 14, 707-722.	0.4	143
43	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	4.5	140
44	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
45	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	1.4	133
46	Association of Cerebral Amyloid-Î ² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
47	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. Brain, 2017, 140, 1466-1485.	3.7	132
48	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology, 2012, 79, 1809-1816.	1.5	129
49	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	3.0	129
50	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
51	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1–42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	1.5	126
52	Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.	1.5	122
53	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.5	122
54	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	1.2	109

4

#	Article	IF	CITATIONS
55	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
56	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping, 2014, 35, 2383-2393.	1.9	108
57	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	3.7	102
58	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	3.0	101
59	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 113-118.	0.9	100
60	Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1857-1863.	1.2	100
61	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.5	100
62	Cerebral perfusion in the predementia stages of Alzheimer's disease. European Radiology, 2016, 26, 506-514.	2.3	99
63	Biobanking of CSF: International standardization to optimize biomarker development. Clinical Biochemistry, 2014, 47, 288-292.	0.8	97
64	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.5	97
65	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
66	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.	4.9	96
67	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology, 2018, 90, e1231-e1239.	1.5	94
68	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 5.	3.0	94
69	STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM. Cytokine, 2002, 19, 228-235.	1.4	92
70	Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neuroscience Letters, 2003, 347, 159-162.	1.0	92
71	In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. Journal of Neuroimmunology, 2005, 161, 190-194.	1.1	90
72	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	0.9	90

#	Article	IF	CITATIONS
73	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
74	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 235-243.	0.9	89
75	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
76	Body fluid biomarkers for multiple sclerosis—the long road to clinical application. Nature Reviews Neurology, 2015, 11, 585-596.	4.9	88
77	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
78	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	3.0	87
79	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	3.0	87
80	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86
81	Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 893-902.	1.5	85
82	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
83	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. The Lancet Healthy Longevity, 2021, 2, e87-e95.	2.0	85
84	Characterization of preâ€analytical sample handling effects on a panel of Alzheimer's disease–related bloodâ€based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.4	84
85	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.4	82
86	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 1-10.	2.3	81
87	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 505-512.	1.2	81
88	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research and Therapy, 2018, 10, 107.	3.0	80
89	α‧ynuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders, 2018, 33, 1724-1733.	2.2	79
90	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Review of Molecular Diagnostics, 2008, 8, 479-494.	1.5	77

#	Article	IF	CITATIONS
91	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease, 2016, 54, 287-295.	1.2	77
92	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Multiple Sclerosis and Related Disorders, 2016, 5, 53-65.	0.9	77
93	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	4.5	77
94	EFNS guidelines on diseaseâ€specific CSF investigations. European Journal of Neurology, 2009, 16, 760.	1.7	73
95	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 319-327.	1.2	73
96	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. PLoS ONE, 2014, 9, e100784.	1.1	72
97	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and pâ€tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
98	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	1.2	71
99	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.4	71
100	CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Multiple Sclerosis Journal, 2013, 19, 436-442.	1.4	70
101	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 412-417.	1.4	70
102	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
103	CSF or Serum Neurofilament Light Added to αâ€ S ynuclein Panel Discriminates Parkinson's From Controls. Movement Disorders, 2020, 35, 288-295.	2.2	69
104	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 86-94.	1.2	68
105	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. Neurobiology of Disease, 2010, 39, 229-241.	2.1	67
106	HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. Acta Neuropathologica, 2013, 126, 237-249.	3.9	66
107	CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer's Disease and Controls. Dementia and Geriatric Cognitive Disorders, 2007, 23, 225-230.	0.7	64
108	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimer's Research and Therapy, 2014, 6, 27.	3.0	63

#	Article	IF	CITATIONS
109	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
110	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. Journal of Alzheimer's Disease, 2017, 56, 687-697.	1.2	60
111	Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population. Alzheimer's Research and Therapy, 2017, 9, 8.	3.0	60
112	Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
113	Diagnostic impact of CSF biomarkers for Alzheimer's disease inÂaÂtertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.4	59
114	Cognitive subtypes of probable Alzheimer's disease robustly identified inÂfour cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.4	59
115	Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. Neuroscience, 2001, 105, 153-167.	1.1	58
116	Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. Journal of Proteomics, 2013, 78, 312-325.	1.2	58
117	Prevalence of the apolipoprotein E Îμ4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
118	Comparison of ELISA- and SIMOA-based quantification of plasma AÎ ² ratios for early detection of cerebral amyloidosis. Alzheimer's Research and Therapy, 2020, 12, 162.	3.0	58
119	<scp>αâ€Synuclein</scp> evokes <scp>NLRP3</scp> inflammasomeâ€mediated <scp>IL</scp> â€1β secretion fi primary human microglia. Glia, 2021, 69, 1413-1428.	rom 2.5	58
120	The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results. BMC Neurology, 2014, 14, 254.	0.8	57
121	The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. Journal of Immunological Methods, 2014, 402, 43-49.	0.6	57
122	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	1.2	57
123	Gut Microbiota Composition Is Related to AD Pathology. Frontiers in Immunology, 2021, 12, 794519.	2.2	57
124	Bloodâ€based metabolic signatures in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 196-207.	1.2	56
125	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1011.e1-1011.e9.	1.5	55
126	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.5	55

#	Article	IF	CITATIONS
127	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	0.9	55
128	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology, 2010, 75, 1617-1622.	1.5	54
129	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.5	54
130	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 383-391.	1.2	53
131	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple Sclerosis International, 2011, 2011, 1-9.	0.4	52
132	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiology of Aging, 2012, 33, 1591-1598.	1.5	52
133	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. Journal of Neurology, 2014, 261, 2338-2343.	1.8	52
134	Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	1.2	52
135	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42 /Aβ40 ratio. , 2017, 13, 885-892.		52
136	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. Neurobiology of Aging, 2018, 61, 75-81.	1.5	52
137	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 563-572.	1.2	52
138	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	1.4	52
139	Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. Journal of Nutrition, Health and Aging, 2003, 7, 153-9.	1.5	52
140	Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. Journal of Neuroimmunology, 2007, 187, 179-186.	1.1	51
141	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. European Journal of Neurology, 2011, 18, 865-871.	1.7	51
142	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.5	51
143	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \hat{l}^2 and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.4	51
144	Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. Neurology, 2021, 97, e930-e940.	1.5	51

#	ARTICLE obligation of Assay Procedures for Analysis of the CSF Biomarkers Amyloid (mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:msub> <mml:mi> î² </mml:mi> <mml:n< th=""><th>IF</th><th>CITATIONS</th></mml:n<></mml:msub></mml:mrow>	IF	CITATIONS
145	Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop.	1.1	50
146	International Journal of Alzheimer's Disease, 2010, 2010, 1-6. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10Âyears. Alzheimer's and Dementia, 2018, 14, 62-70.	0.4	50
147	Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro-Oncology, 2018, 20, 1494-1504.	0.6	50
148	Metabolic Age Based on the BBMRI-NL ¹ H-NMR Metabolomics Repository as Biomarker of Age-related Disease. Circulation Genomic and Precision Medicine, 2020, 13, 541-547.	1.6	50
149	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
150	Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer's disease. Scientific Reports, 2021, 11, 9736.	1.6	49
151	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression. PLoS ONE, 2013, 8, e70019.	1.1	48
152	Poly(GP), neurofilament and grey matter deficits in <i>C9orf72</i> expansion carriers. Annals of Clinical and Translational Neurology, 2018, 5, 583-597.	1.7	48
153	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	3.0	48
154	Sex differences in CSF biomarkers vary by Alzheimer disease stage and <i>APOE</i> ε4 genotype. Neurology, 2020, 95, e2378-e2388.	1.5	48
155	Tracking disease progression nonâ€invasively in Duchenne and Becker muscular dystrophies. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 715-726.	2.9	47
156	Serum homocysteine levels in relation to clinical progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1349-1353.	0.9	46
157	Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Multiple Sclerosis Journal, 2011, 17, 838-850.	1.4	46
158	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1596-1604.	1.5	46
159	Clinical phenotype, atrophy, and small vessel disease in <i>APOE</i> ε2 carriers with Alzheimer disease. Neurology, 2018, 91, e1851-e1859.	1.5	46
160	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
161	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	4.4	46
162	24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2007, 85, 1499-1505.	1.3	45

#	Article	IF	CITATIONS
163	SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	1.4	45
164	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Scientific Reports, 2017, 7, 13333.	1.6	45
165	Contactins in the central nervous system: role in health and disease. Neural Regeneration Research, 2019, 14, 206.	1.6	45
166	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging, 2018, 61, 198-206.	1.5	44
167	Antibodyâ€based methods for the measurement of αâ€synuclein concentration in human cerebrospinal fluid – method comparison and round robin study. Journal of Neurochemistry, 2019, 149, 126-138.	2.1	44
168	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. Neurology, 2021, 97, e1276-e1287.	1.5	44
169	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 809-813.	1.2	42
170	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiology of Aging, 2019, 84, 225-234.	1.5	42
171	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
172	The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. Trials, 2013, 14, 250.	0.7	41
173	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. Journal of Alzheimer's Disease, 2016, 55, 585-595.	1.2	41
174	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. Journal of Neuroinflammation, 2017, 14, 235.	3.1	41
175	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.5	41
176	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping, 2018, 39, 3143-3151.	1.9	40
177	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
178	Discordant amyloid-Î ² PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	3.0	40
179	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 86-98.	2.7	40
180	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. Journal of Neurology, 2007, 254, 631-637.	1.8	39

#	Article	IF	CITATIONS
181	Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nature Communications, 2019, 10, 2240.	5.8	39
182	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods, 2012, 56, 508-513.	1.9	38
183	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 573-595.	1.4	38
184	Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine, 2002, 19, 228-35.	1.4	38
185	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry, 2018, 64, 927-937.	1.5	37
186	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
187	Personalized extended interval dosing of natalizumab in MS. Neurology, 2020, 95, e745-e754.	1.5	36
188	Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. Clinical Cancer Research, 2022, 28, 1572-1585.	3.2	36
189	Endogeneous peptide profiling of cerebrospinal fluid by MALDIâ€TOF mass spectrometry: Optimization of magnetic beadâ€based peptide capture and analysis of preanalytical variables. Proteomics - Clinical Applications, 2007, 1, 1385-1392.	0.8	35
190	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	1.2	35
191	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2020, 89, 99-107.	1.5	34
192	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Multiple Sclerosis Journal, 2022, 28, 1121-1125.	1.4	34
193	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
194	The plasma peptides of ovarian cancer. Clinical Proteomics, 2018, 15, 41.	1.1	33
195	Stateâ€ofâ€ŧheâ€art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.4	33
196	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. Movement Disorders, 2020, 35, 859-867.	2.2	33
197	Quantitative proteomics suggests decrease in the secretograninâ€1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics, 2015, 15, 3361-3369.	1.3	32
198	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.4	32

#	Article	IF	CITATIONS
199	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatricÂdisorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 99-106.	1.2	32
200	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain, 2018, 141, 3377-3388.	3.7	32
201	Fingerprinting Alzheimer's Disease by ¹ H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. Journal of Proteome Research, 2020, 19, 1696-1705.	1.8	32
202	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e1898-e1905.	1.5	32
203	Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.	3.0	31
204	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.5	31
205	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	0.6	30
206	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology, 2014, 83, 1210-1216.	1.5	30
207	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. Multiple Sclerosis Journal, 2018, 24, 472-480.	1.4	30
208	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	3.0	30
209	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.2	30
210	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
211	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	1.7	29
212	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	3.3	29
213	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	1.7	28
214	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.4	28
215	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
216	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	28

#	Article	IF	CITATIONS
217	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
218	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	1.2	27
219	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 309-320.	1.2	27
220	The Bri2 and Bri3 BRICHOS Domains Interact Differently with Aβ42 and Alzheimer Amyloid Plaques. Journal of Alzheimer's Disease Reports, 2018, 2, 27-39.	1.2	27
221	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. Neuron, 2022, 110, 1009-1022.e4.	3.8	27
222	Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. Clinical Chemistry and Laboratory Medicine, 2005, 43, 1089-95.	1.4	26
223	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1079-1083.	1.1	26
224	CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiology of Aging, 2017, 57, 186-194.	1.5	26
225	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. International Journal of Molecular Sciences, 2019, 20, 4674.	1.8	26
226	Comparing CSF amyloidâ€beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12182.	1.2	26
227	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. Journal of Neuroinflammation, 2022, 19, 50.	3.1	26
228	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
229	Discriminatory and predictive capabilities of enzymeâ€linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimer's and Dementia, 2013, 9, 276-283.	0.4	25
230	Characterising user preference for white LED light sources with CIE colour rendering index combined with a relative gamut area index. Lighting Research and Technology, 2017, 49, 461-480.	1.2	25
231	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	3.0	25
232	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	1.1	25
233	Retinal thickness as a potential biomarker in patients with amyloidâ€proven early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 463-471.	1.2	25
234	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. Nutrients, 2019, 11, 1161.	1.7	25

#	Article	IF	CITATIONS
235	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	1.2	25
236	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. Frontiers in Neurology, 2015, 6, 202.	1.1	24
237	Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. Alzheimer's Research and Therapy, 2017, 9, 38.	3.0	24
238	Serum Neurofilament light correlates with CADASIL disease severity and survival. Annals of Clinical and Translational Neurology, 2019, 6, 46-56.	1.7	24
239	The neurofilament light chain is not stable in vitro. Annals of Neurology, 2011, 69, 1065-1066.	2.8	23
240	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
241	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 625-632.	1.4	23
242	Preâ€amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 2018, 5, 1037-1047.	1.7	23
243	Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research and Therapy, 2019, 11, 83.	3.0	23
244	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8.	3.0	23
245	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. Alzheimer's Research and Therapy, 2020, 12, 44.	3.0	23
246	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23
247	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	1.8	23
248	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. Neuropathology and Applied Neurobiology, 2006, 32, 318-331.	1.8	22
249	Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. Medicine (United States), 2016, 95, e3093.	0.4	22
250	The plasma peptidome. Clinical Proteomics, 2018, 15, 39.	1.1	22
251	Pre-analytical stability of serum biomarkers forÂneurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1. Clinical Chemistry and Laboratory Medicine, 2022, 60, 842-850.	1.4	22
252	Role of BRI2 in Dementia. Journal of Alzheimer's Disease, 2014, 40, 481-494.	1.2	21

#	Article	IF	CITATIONS
253	Effect of longâ€term storage in biobanks on cerebrospinal fluid biomarker Aβ _{1â€42} , Tâ€tau, and Pâ€tau values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 45-50.	1.2	21
254	CNS penetration of ART in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2018, 73, 484-489.	1.3	21
255	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	3.0	21
256	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. Journal of Psychiatric Research, 2018, 104, 183-191.	1.5	21
257	The use of cerebrospinal fluid in biomarker studies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 3-20.	1.0	21
258	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	1.7	21
259	PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	3.0	21
260	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. Journal of Neurology, 2020, 267, 144-152.	1.8	21
261	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. Alzheimer's Research and Therapy, 2021, 13, 53.	3.0	21
262	Evaluation of 3-nitrotyrosine as a marker for 3-nitropropionic acid-induced oxidative stress in Lewis and Wistar rats and strain-specific whole brain spheroid cultures. Brain Research, 2002, 931, 5-20.	1.1	20
263	Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. Annals of Neurology, 2017, 81, 749-753.	2.8	20
264	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 23.	3.0	20
265	Novel <scp>CSF</scp> biomarkers to discriminate <scp>FTLD</scp> and its pathological subtypes. Annals of Clinical and Translational Neurology, 2018, 5, 1163-1175.	1.7	20
266	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	2.8	20
267	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. International Journal of Molecular Sciences, 2021, 22, 13136.	1.8	20
268	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
269	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 201-209.	1.2	19
270	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 139-146.	1.2	19

#	Article	IF	CITATIONS
271	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881953.	O.5	19
272	Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. Methods in Molecular Biology, 2019, 2044, 27-50.	0.4	19
273	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
274	Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 2127-2136.	1.7	19
275	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	19
276	Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 47, 102666.	0.9	19
277	Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	3.0	19
278	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. Brain, 2022, 145, 4056-4064.	3.7	19
279	Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials. PLoS ONE, 2022, 17, e0264557.	1.1	19
280	Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2015, 21, 481-484.	1.4	18
281	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. Journal of Alzheimer's Disease, 2015, 44, 153-162.	1.2	18
282	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
283	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 52.	3.0	18
284	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. Alzheimer's Research and Therapy, 2020, 12, 116.	3.0	18
285	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. Alzheimer's Research and Therapy, 2021, 13, 2.	3.0	18
286	The plasma peptides of Alzheimer's disease. Clinical Proteomics, 2021, 18, 17.	1.1	18
287	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain, 2022, 145, 105-118.	3.7	18
288	Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure. Journal of the Neurological Sciences, 2011, 307, 132-138.	0.3	17

#	Article	IF	CITATIONS
289	Validation of soluble amyloidâ€ î ² precursor protein assays as diagnostic <scp>CSF</scp> biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.	2.1	17
290	Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. Cytokine, 2017, 91, 145-152.	1.4	17
291	Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV. Scientific Reports, 2019, 9, 8004.	1.6	17
292	Amyloidâ€ <i>β</i> PET and CSF in an autopsyâ€confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	1.7	17
293	Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression. Journal of Psychiatric Research, 2020, 130, 424-432.	1.5	17
294	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
295	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. Antioxidants, 2020, 9, 456.	2.2	17
296	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimer's and Dementia, 2021, 17, 205-214.	0.4	17
297	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimer's Research and Therapy, 2021, 13, 101.	3.0	17
298	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1513.e1-1513.e17.	1.2	17
299	The global Alzheimer's Association round robin study on plasma amyloid β methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242.	1.2	17
300	Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
301	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. Neurology, 2022, 98, .	1.5	17
302	Whole brain spheroid cultures as a model to study the development of nitric oxide synthase-guanylate cyclase signal transduction. Developmental Brain Research, 2000, 125, 99-115.	2.1	16
303	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2010, 2010, 1-12.	1.1	16
304	Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Multiple Sclerosis Journal, 2012, 18, 1092-1098.	1.4	16
305	Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. Multiple Sclerosis and Related Disorders, 2014, 3, 533-541.	0.9	16
306	The plasma peptides of breast versus ovarian cancer. Clinical Proteomics, 2019, 16, 43.	1.1	16

#	Article	IF	CITATIONS
307	Risk of dementia in <i>APOE</i> Îμ4 carriers is mitigated by a polygenic risk score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12229.	1.2	16
308	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). Clinical Biochemistry, 2017, 50, 1061-1066.	0.8	16
309	Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells, 2021, 10, 38.	1.8	16
310	Design of the ExCersionâ€VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 157-165.	1.8	15
311	Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?. Journal of Neuroinflammation, 2017, 14, 257.	3.1	15
312	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15
313	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12314.	1.2	15
314	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 261-270.	1.2	14
315	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis, 2016, 8, 2243-2254.	0.6	14
316	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging, 2019, 77, 58-65.	1.5	14
317	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 1-9.	1.2	14
318	Blood platelet RNA enables the detection of multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732094678.	0.5	14
319	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. Biomolecules, 2020, 10, 1177.	1.8	14
320	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
321	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	1.5	14
322	New developments of biofluidâ€based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 2292-2307.	0.4	14
323	Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease. Neuroscience Letters, 2015, 589, 47-51.	1.0	13
324	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 87.	3.0	13

#	Article	IF	CITATIONS
325	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
326	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	1.2	13
327	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
328	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis Journal, 2022, 28, 102-110.	1.4	13
329	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 108, 99-109.	1.5	13
330	Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases. Advances in Experimental Medicine and Biology, 2015, 864, 79-93.	0.8	12
331	Lumbar puncture in patients with neurologic conditions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 108-110.	1.2	12
332	The appreciation of LED-based white light sources by Dutch and Chinese people in three application areas. Lighting Research and Technology, 2019, 51, 353-372.	1.2	12
333	ApoE and clusterin CSF levels influence associations between APOEÂgenotype and changes in CSF tau, but not CSF Aβ42, levels inÂnon-demented elderly. Neurobiology of Aging, 2019, 79, 101-109.	1.5	12
334	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. Alzheimer's Research and Therapy, 2021, 13, 38.	3.0	12
335	Techniques, Contraindications, and Complications of CSF Collection Procedures. , 2015, , 35-57.		12
336	Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials. Neurotherapeutics, 2021, 18, 2351-2367.	2.1	12
337	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
338	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy ofÂBiomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 889-899.	1.2	11
339	Standard biobanking conditions prevent evaporation of body fluid samples. Clinica Chimica Acta, 2015, 442, 141-145.	0.5	11
340	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 2017, 60, 201-210.	1.2	11
341	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
342	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2019, 86, 322-324.	2.8	11

#	ARTICLE	IF	CITATIONS
343	A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. International Journal of Molecular Sciences, 2022, 23, 7221.	1.8	11
344	Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated Wistar and Lewis rats. Neurochemical Research, 2001, 26, 1237-1244.	1.6	10
345	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
346	Multicenter Analytical Validation of AÎ ² 40 Immunoassays. Frontiers in Neurology, 2017, 8, 310.	1.1	10
347	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology, 2019, 92, e2699-e2705.	1.5	10
348	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. Journal of the American Medical Directors Association, 2023, 24, 638-644.e1.	1.2	10
349	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. International Journal of Molecular Sciences, 2021, 22, 2931.	1.8	10
350	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110138.	0.5	10
351	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 83, 269-279.	1.2	10
352	CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	10
353	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology, 2022, 98, .	1.5	10
354	Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE). Frontiers in Neurology, 0, 13, .	1.1	10
355	The inflammatory marker GDF-15 is not independently associated with late-life depression. Journal of Psychosomatic Research, 2016, 83, 46-49.	1.2	9
356	Brain endothelial cell expression of SPARCLâ€1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators <i>in vitro</i> . Neuropathology and Applied Neurobiology, 2018, 44, 404-416.	1.8	9
357	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	0.5	9
358	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. Metabolites, 2019, 9, 236.	1.3	9
359	Neurofilament light chain as biomarker in idiopathic intracranial hypertension. Cephalalgia, 2020, 40, 1346-1354.	1.8	9
360	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12063.	1.2	9

#	ARTICLE	IF	CITATIONS
361	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
362	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomarkers in Medicine, 2007, 1, 111-119.	0.6	8
363	Computerâ€essisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	1.2	8
364	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. Neurology and Therapy, 2019, 8, 129-145.	1.4	8
365	Why Is Amyloid-Î ² PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	1.2	8
366	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31.	1.2	8
367	Targeting hippocampal hyperactivity with real-time fMRI neurofeedback: protocol of a single-blind randomized controlled trial in mild cognitive impairment. BMC Psychiatry, 2021, 21, 87.	1.1	8
368	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. Frontiers in Aging Neuroscience, 2021, 13, 638718.	1.7	8
369	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. Journal of Alzheimer's Disease, 2021, 82, 381-390.	1.2	8
370	Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. Journal of Neurology, 2022, 269, 3700-3705.	1.8	8
371	miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis. Cells, 2022, 11, 1551.	1.8	8
372	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.5	8
373	Short commentary on â€~a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Multiple Sclerosis Journal, 2010, 16, 129-132.	1.4	7
374	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson′s Disease. International Journal of Molecular Sciences, 2020, 21, 8519.	1.8	7
375	Plasma p-tau217: from â€~new kid' to most promising candidate for Alzheimer's disease blood test. Brain, 2020, 143, 3170-3172.	3.7	7
376	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
377	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging, 2020, 93, 144.e1-144.e15.	1.5	7
378	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	1.1	7

#	Article	IF	CITATIONS
379	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. Biomedicine Hub, 2020, 5, 1-22.	0.4	7
380	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12120.	1.2	7
381	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
382	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
383	Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 849-857.	0.9	7
384	Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice. Respiratory Research, 2015, 16, 119.	1.4	6
385	Importance of Pre-analytical Stability for CSF Biomarker Testing. , 2015, , 59-77.		6
386	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2017, 50, 77-86.	1.5	6
387	High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients. Journal of NeuroVirology, 2020, 26, 572-580.	1.0	6
388	Concatenating plasma p-tau to Alzheimer's disease. Brain, 2021, 144, 14-17.	3.7	6
389	Biomarker testing in MCI patients—deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	3.0	6
390	Serum Contactin-1 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1040.	3.1	6
391	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2021, 108, 146-154.	1.5	6
392	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	6
393	Biomarkers for Alzheimer's disease. Which way to go?. Neurobiology of Aging, 2004, 25, 695-696.	1.5	5
394	Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. Journal of Neuroscience Methods, 2010, 193, 296-299.	1.3	5
395	Recent progress in omics-driven analysis of MS to unravel pathological mechanisms. Expert Review of Neurotherapeutics, 2013, 13, 1001-1016.	1.4	5
396	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 53, 107-116.	1.2	5

#	Article	IF	CITATIONS
397	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 492-500.	1.8	5
398	Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12127.	1.8	5
399	Use of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic. Canadian Journal of Neurological Sciences, 2022, 49, 203-209.	0.3	5
400	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102840.	0.9	5
401	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103364.	0.9	5
402	The NeuroMET project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.4	5
403	Subjective cognitive decline and selfâ€reported sleep problems: The SCIENCe project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	5
404	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimer's Research and Therapy, 2022, 14, .	3.0	5
405	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 75-80.	1.2	4
406	New <scp>CSF</scp> biomarkers on the block. EMBO Molecular Medicine, 2016, 8, 1118-1119.	3.3	4
407	Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	1.8	4
408	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV. , 2017, 58, 5985.		4
409	O3â€09â€06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1â€42 AND 1â€40 ISOFORMS DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS. Alzheimer's and Dementia, 2018, 14, P1039.	CAN 0.4	4
410	Diurnal Cortisol Secretion Is Not Related to Multiple Sclerosis-Related Fatigue. Frontiers in Neurology, 2020, 10, 1363.	1.1	4
411	Effect of driving speed on target visibility under mesopic conditions using a driving simulator. Lighting Research and Technology, 2021, 53, 231-248.	1.2	4
412	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	4
413	Fluid biomarkers for disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1660-1661.	1.4	4
414	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. Brain Communications, 2022, 4, fcac026.	1.5	4

#	Article	IF	CITATIONS
415	Effects of age, amyloid, sex, and <i>APOE</i> Îμ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	1.2	4
416	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
417	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.1	3
418	P4â€⊋24: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.4	3
419	[O3–10–03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.4	3
420	No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients. Frontiers in Molecular Neuroscience, 2018, 11, 371.	1.4	3
421	Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients. Medical Sciences (Basel, Switzerland), 2018, 6, 108.	1.3	3
422	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population― Annals of Neurology, 2020, 87, 155-155.	2.8	3
423	Contactins & Alzheimer's Disease: Synaptic Proteins, Contactins may Contribute to the Pathology of Alzheimer's Disease. Neuroscience, 2020, 424, 182-183.	1.1	3
424	Using cerebrospinal fluid amyloidâ€beta (1â€42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. Alzheimer's and Dementia, 2020, 16, e045128.	0.4	3
425	A biorepository for the inâ€depth validation of preâ€analytical sample handling effects on novel bloodâ€based biomarkers for Alzheimer's disease: The first results. Alzheimer's and Dementia, 2020, 16, e045763.	0.4	3
426	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. Biomolecules, 2021, 11, 1484.	1.8	3
427	CSF proteomic signature predicts progression to Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12240.	1.8	3
428	Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid. Neurobiology of Disease, 2022, 172, 105813.	2.1	3
429	Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. Journal of Neuroimmunology, 2012, 251, 103-106.	1.1	2
430	[P1–243]: ALPHAâ€SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES Alzheimer's and Dementia, 2017, 13, P338.	0.4	2
431	Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. Journal of Alzheimer's Disease, 2019, 71, 15-20.	1.2	2
432	Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1â€42, Aβ1â€40, GFAP and NF‣ in blood. Alzheimer's and Dementia, 2020, 16, e043506.	0.4	2

#	Article	IF	CITATIONS
433	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. Alzheimer's and Dementia, 2020, 16, .	0.4	2
434	Plasma Neurofilament Light Is Not Associated with Ongoing Neuroaxonal Injury or Cognitive Decline in Perinatally HIV Infected Adolescents: A Brief Report. Viruses, 2022, 14, 671.	1.5	2
435	NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 243-249.	0.6	2
436	Determining the Minimal Important Change of Everyday Functioning in Dementia. Neurology, 2022, 99, .	1.5	2
437	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
438	Guidelines on Cerebrospinal Fluid Analysis. , 2015, , 407-428.		1
439	P2â€166: Retinal Thickness in Alzheimer′s Disease: A Potential Diagnostic Biomarker? Evidence from an Amyloid Proven Early Onset Alzheimer′s Disease Cohort. Alzheimer's and Dementia, 2016, 12, P678.	0.4	1
440	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
441	[ICâ€Pâ€005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€Î² AND [¹⁸ F]FLORBE PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	TABEN 0.4	1
442	[P2–338]: ARE NEUROFILAMENT LIGHT CHAIN AND WHITE MATTER INTEGRITY RELATED BIOMARKERS FOR FAMILIAL FRONTOTEMPORAL DEMENTIA?. Alzheimer's and Dementia, 2017, 13, P751.	0.4	1
443	P1â€247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER I NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS. Alzheimer's and Dementia, 2018, 14, P373.	N 0.4	1
444	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
445	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. Alzheimer's and Dementia, 2020, 16, e039094.	0.4	1
446	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project. Alzheimer's and Dementia, 2020, 16, e044783.	0.4	1
447	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1
448	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. Alzheimer's and Dementia, 2020, 16, e045230.	0.4	1
449	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. Alzheimer's and Dementia, 2020, 16, e045829.	0.4	1
450	Prediction of amyloid PET status using the LUMIPULSE G βâ€amyloid ratio (1â€42/1â€40). Alzheimer's and Dementia, 2020, 16, e046006.	0.4	1

#	Article	IF	CITATIONS
451	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
452	CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2020, 16, e047247.	0.4	1
453	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1436-1438.	1.2	1
454	Pre-analytical sample handling effects on blood cytokine levels: quality control of a COVID-19 biobank. Biomarkers in Medicine, 2021, 15, 987-997.	0.6	1
455	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. Alzheimer's and Dementia, 2021, 17, .	0.4	1
456	Associations between gut microbiota composition and AD biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	1
457	Plasma NfL trajectory during ICUâ€ŧreatment of COVIDâ€19 patients: A prospective cohort study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
458	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
459	S4-01-04: INTERNATIONAL STANDARDIZATION TO OBTAIN THE BEST POSSIBLE CSF BIOMARKERS. , 2014, 10, P239-P239.		0
460	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.		0
461	P4-278: IDENTIFICATION OF NOVEL DIAGNOSTIC CSF PROTEIN BIOMARKERS FOR FTD WITH HIGH DISCRIMINATORY POWER. , 2014, 10, P886-P886.		0
462	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.		0
463	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
464	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
465	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
466	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.		0
467	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
468	P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example. , 2015, 11, P387-P387.		0

#	Article	IF	CITATIONS
469	P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease. , 2015, 11, P873-P873.		0
470	O4-11-01: Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of $Al^2(1-42)$ in human cerebrospinal fluid. , 2015, 11, P295-P296.		0
471	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0
472	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
473	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
474	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.		0
475	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
476	O3â€08â€01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.4	0
477	ICâ€Pâ€103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0
478	P3â€144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.4	0
479	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.4	0
480	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease. , 2016, 12, P169-P170.		0
481	O1â€05â€02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU. Alzheimer's and Dementia, 2016, 12, P183.	0.4	0
482	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, P355-P355.		0
483	O5â€05â€03: Novel CSF Biomarkers Discriminating FTLDâ€TDP from Nonâ€Demented Controls. Alzheimer's and Dementia, 2016, 12, P388.	0.4	0
484	P1â€174: Costâ€Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, P469.	0.4	0
485	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0
486	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.4	0

#	Article	IF	CITATIONS
487	[P4–146]: NEUROFILAMENT LIGHT CHAIN AND PHOSPHOTAU/TAU RATIO AS CSF BIOMARKERS IN FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1313.	0.4	0
488	[P4–151]: ALPHAâ€SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER‣ABORATOR PRECISION USING A NEW COLORIMETRIC ELISA. Alzheimer's and Dementia, 2017, 13, P1316.	۲ _{0.4}	0
489	[P2–245]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN. Alzheimer's and Dementia, 2017, 13, P705.	0.4	0
490	[P3–161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL Aβ CLEARANCE?. Alzheimer's and Dementia, 2017, 13 P995.	³ ,0.4	0
491	[P3–226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. Alzheimer's and Dementia, 2017, 13, P1024.	0.4	0
492	[ICâ€₽â€055]: EFFECT OF APOEâ€ἷµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.4	0
493	[ICâ€Pâ€058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
494	[P1–250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.4	0
495	[P1–276]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY. Alzheimer's and Dementia, 2017, 13, P355.	0.4	0
496	[P2–203]: SPPL2B: A NOVEL PROTEIN RELATED TO TAU PATHOLOGY IN ALZHEIMER's DISEASE?. Alzheimer's and Dementia, 2017, 13, P684.	0.4	0
497	[P2–207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€Î² AND [¹⁸ F]FLORBETA PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	BEN O.4	0
498	[P2–242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P704.	0.4	0
499	[P2–249]: CONTACTINâ€I IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NONâ€DEMENTED CONTROLS. Alzheimer's and Dementia, 2017, 13, P708.	0.4	0
500	[P2–335]: EFFECT OF APOE ε2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
501	[F1–03–04]: BIOMARKERâ€BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNI DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	TIVE 0.4	0
502	[O1–05–03]: CSF AMYLOID BETA 1–42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€ÐEPENE UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	DENT 0.4	0
503	[O1–05–04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY. Alzheimer's and Dementia, 2017, 13, P199.	0.4	0
504	[O2–01–01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.4	0

#	Article	IF	CITATIONS
505	[O2–05–01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.4	0
506	[O2–10–06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	L _{0.4}	0
507	[P2–194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.4	0
508	[P3–075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
509	O1â€10â€06: CONTACTINâ€1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FRO ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P245.	M 0.4	Ο
510	F2â€02â€04: NEUROFILAMENTS TO MEASURE TREATMENT EFFICACY IN MS. Alzheimer's and Dementia, 2018, 14 P604.	, 0.4	0
511	P2â€248: CONTACTINâ€2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P768.	0.4	0
512	P2â€⊋28: PREâ€ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P755.	0.4	0
513	O2â€04â€02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOII BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P621.	D _{0.4}	0
514	P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2018, 14, P533.	0.4	0
515	P1â€297: METABOLIC BLOODâ€BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P401.	0.4	0
516	P3â€289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€5CD STUDY. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
517	O2â€09â€03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIME DISEASE BIOMARKERS IN A NONâ€ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P641.	ER'S 0.4	0
518	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OI BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	F 0.4	0
519	DTâ€02â€02: NOVEL ULTRASENSITIVE IMMUNOASSAY DETECTING Pâ€TAU THR217 COMPLETELY DISTINGUISHE: ALZHEIMER'S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION. Alzheimer's and Dementia, 2018, 14, P1669.	S 0.4	0
520	O2â€14â€04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATEâ€ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. Alzheimer's and Dementia, 2018, 14, P657.	0.4	0
521	O2â€15â€06: CSF AMYLOIDâ€Î² PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. Alzheir and Dementia, 2018, 14, P663.	mer's 0.4	0
522	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. Alzheimer's and Dementia, 2018, 14, P1060.	⁺ 0.4	0

#	Article	IF	CITATIONS
523	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
524	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.4	0
525	P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. Alzheimer's and Dementia, 2018, 14, P789.	0.4	0
526	F4â€08â€01: PLASMA AMYLOID AS A PREâ€5CREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITI DECLINE. Alzheimer's and Dementia, 2018, 14, P1394.	VE 0.4	0
527	O2â€09â€04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF αâ€SYNUCLEIN IN F CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH. Alzheimer's and Dementia, 2018, 14, P642.	IUMAN 0.4	Ο
528	gMS-Classifier1 does not predict disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1010-1011.	1.4	0
529	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. Clinica Chimica Acta, 2020, 502, 199-200.	0.5	0
530	CSF proteomic changes in preâ€preclinical Alzheimer's disease: A monozygotic twin study. Alzheimer's and Dementia, 2020, 16, e038966.	0.4	0
531	Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEvELOP baseline results. Alzheimer's and Dementia, 2020, 16, e039306.	0.4	0
532	Singleâ€cell profiling of circulating and brainâ€resident immune cells in a mouse model for amyloidosis and in aged mice. Alzheimer's and Dementia, 2020, 16, e041789.	0.4	0
533	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project. Alzheimer's and Dementia, 2020, 16, e042116.	0.4	0
534	BDNFâ€Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCe Project. Alzheimer's and Dementia, 2020, 16, e042728.	0.4	0
535	Localization and protein levels of YKLâ€40 in postmortem brain of frontotemporal dementia and Alzheimer's disease cases. Alzheimer's and Dementia, 2020, 16, e044523.	0.4	0
536	Comparison of two analytical platforms for bloodâ€based surrogate biomarkers of amyloid pathology. Alzheimer's and Dementia, 2020, 16, e045110.	0.4	0
537	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. Alzheimer's and Dementia, 2020, 16, e045112.	0.4	0
538	Serum neurofilament light in memory clinic practice. Alzheimer's and Dementia, 2020, 16, e045155.	0.4	0
539	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in nonâ€demented memory clinic participants. Alzheimer's and Dementia, 2020, 16, e045196.	0.4	0
540	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e045470.	0.4	0

#	Article	IF	CITATIONS
541	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. Alzheimer's and Dementia, 2020, 16, e045719.	0.4	0
542	Plasma amyloidâ€Î² oligomerization assay as a screening test for abnormal amyloid status. Alzheimer's and Dementia, 2020, 16, e045754.	0.4	0
543	Comparative diagnostic performance of plasma Pâ€ŧau217 and Pâ€ŧau181 in Alzheimer's disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipirâ€PET uptake. Alzheimer's and Dementia, 2020, 16, e045755.	0.4	0
544	CSF biomarkers for frontotemporal dementia and its pathological subtypes. Alzheimer's and Dementia, 2020, 16, e045851.	0.4	0
545	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.4	0
546	Pre-Analytical Processing and Biobanking Protocol for CSF Samples. Neuromethods, 2021, , 137-145.	0.2	0
547	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. Journal of Alzheimer's Disease, 2021, 83, 1367-1377.	1.2	0
548	Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 2022, 98, 471-471.	1.5	0
549	Clinical and analytical comparison of three assays for plasma pâ€ŧau isoforms on an ultrasensitive platform. Alzheimer's and Dementia, 2021, 17, .	0.4	0
550	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. Alzheimer's and Dementia, 2021, 17, .	0.4	0
551	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
552	Is A+T―Alzheimer's disease or not? A combined CSF and pathology study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
553	A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
554	Preâ€analytical and clinical validation on the highway to implementation of novel dementia blood tests. Alzheimer's and Dementia, 2021, 17, .	0.4	0
555	Novel CSF inflammatory markers MIF and TREMâ€1 are increased in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
556	Apolipoprotein L1 is increased in frontotemporal lobar degeneration postmortem brain tissue but not in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, .	0.4	0
557	Subjective cognitive decline and selfâ€ r eported sleep at a memory clinic: The SCIENCe project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
558	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
559	Alzheimer's disease genetic risk variants show brain cell typeâ€specific associations with protein levels in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, e049531.	0.4	Ο
560	Plasma Pâ€ŧau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. Alzheimer's and Dementia, 2021, 17, .	0.4	0
561	Predicting institutionalization and mortality across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
562	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
563	Stability of the novel bloodâ€based biomarkers under preâ€analytical sample handling conditions: Results of the SABBâ€GBSC working group. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
564	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.4	0